Share This
Create Your Own Business Intelligence Website
 
Input the stock code or the company name     Search  

<00460.HK> - Sihuan Pharmaceutical Holdings Group Ltd.

 
 
 Basic Datum
Company name Lot P/E P/B EPS DPS
SIHUAN PHARM 1000 14.68 2.1753 0.1867 0.1189
Profile Information Data Financial Ratios Profit Loss Cash Flow Balance Earnings Dividend
 
 
 
 Company Rating
Date Broker Company name Rating Target
≫More
 
 Company performance - Published
Date Company name Turnover* Profit* % Dividend
≫More
 
 Comment
2020-07-07 北京疫情反彈,藥股普漲。於10:00國藥控股升10.8%或2.05港元,報21.05港元;四環醫藥升6%或0.05港元,報0.88%;綠葉制藥升5.4%或0.24港元,報4.7港元;華潤醫藥升4.7%或0.21港元,報4.71港元;康哲藥業升3.5%或0.33港元,報9.76港元;復星醫藥升3.2%或0.85港元,報27.1港元;白雲山升3.1%或0.65港元,報21.65港元。
 
2020-07-07 中國生物制藥升5.6%或0.64港元,報12港元;四環醫藥升5.5%或0.04港元,報0.77港元;三生制藥升5.1%或0.44港元,報9.14港元;金斯瑞生物科技升4.6%或0.74港元,報16.72港元。
 
2020-07-14 四環醫藥公布公告,集團開發的重酒石酸卡巴拉汀膠囊及左乙拉西坦片已取得中國國家藥品監督管理局頒發的藥品生產批件,咪達唑侖口頰黏膜溶液則取得藥品注冊批件。四環醫藥為中國首家取得咪達唑侖口頰黏膜溶液注冊批件的企業。
 
2020-07-28  四環醫藥控股集團有限公司(港交所股權代號:0460,「四環醫藥」或「本公司」),中國領先的心腦血管藥物制藥公司之一,宣布其間接附屬公司 -- 山東軒竹醫藥科技有限公司(「山東軒竹」)所開發的碳青霉烯類新型抗感染藥「艾帕培南」得到國家食品藥品監督管理局頒發臨床批件。此外,該項目已成功進行轉讓,為集團帶來理想的投資回報。
 
2020-08-04 四環醫藥獲SMART TOP OVERSEAS LIMITED於7月22日在場內以每股平均價0.8234港元賣入666.2萬股,涉資約548.55萬港元。賣入後,SMART TOP OVERSEAS LIMITED的最新持股數目為5,975,747,699股,持股比例由63.06%升至63.13%。
 
 
 Top Gain / Loss Show All Charts 
 
 Value
Name Updated Value Change Change %
HSI 08-14 16:08 25183  47.66  0.19%
SIHUAN PHARM 08-14 16:08 0.84  0.02  2.33%
≫More
 
 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2020Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.